ASXL1 and leukemia: A closer look into the mutations that persisted following therapy (at remission) in responders revealed that they were in genes associated with pre‐leukaemia (ASXL1, DNMT3A, IDH2, SRSF2 and TET2) [11, 12, 13, 14, 15, 16] (Figure 1E).